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Small interfering RNA (siRNA)-mediated gene silencing has
become a drug development paradigm.1 It has entered clinical trials
unusually fast, through chemical2 and medical experience built on
previous nucleic acid based drug candidates. Meanwhile it is also
rediscovering the fact that nucleic acids per se do not enter intact
human cells.
Cationic vectors developed earlier for gene delivery are
multifunctional: they bind their cargo tightly Via electrostatic
forces; excess cationic charges borne by the nanoparticles so
formed coaggregate anionic heparan sulfate proteoglycans
(HSPG) of the cell surface,3 thus triggering endocytosis.
Subsequently, membrane-disturbing4 or endosome-swelling5
properties borne by the vector release some of the engulfed
material into the cytoplasm.
siRNAs are a 100-fold smaller than genes. The cargo-to-carrier
electrostatic binding is weakened to the same extent, favoring
unwanted extracellular exchange of the small nucleic acid for any
larger polyanion.6 However, carriers are easier to link chemically
to oligos than to genes. Such molecular conjugates7 are expected
to display a more classical pharmacology and a better efficiency/
inflammation balance than supramolecular particles, including
polyethyleneglycol-coated lipoplexes.8,9
Several oligocation-conjugated siRNAs have been described
recently,10-13 but all still bear a global negative charge and hence
are unable to enter cells according to the mechanism described
above. We recently developed a stepwise automated synthesis of
oligodeoxyribonucleotide-oligospermines that allows incorporation
of any number of spermine residues at any position of an
oligonucleotide. It makes use of a DMT-spermine phosphoramid-
ite14 in addition to the four nucleic bases synthons. The synthesis
was adapted to ribonucleic acids, and spermine coupling yields were
improved for the synthesis of the larger oligomers used here (see
Figure 1 and Supporting Information).
For proof-of-principle, we synthesized a fluorescent 3′-FAM 19-
mer oligodeoxyribonucleotide 5′-conjugated to a stretch of 18
spermines S18[dN]19 (Figure 1) and observed its fate in HeLa cells
under a fluorescence microscope (Figure 2a). After 4 h of
incubation, cells showed, besides intracellular fluorescent vacuoles,
a diffuse fluorescent halo throughout their cytoplasm, with a nuclear
rim and nucleoli accumulation. Cell entry via HSPG-mediated
endocytosis requires an overall cationic charge balance. Further-
more, subsequent endosome swelling and rupture require a fraction
of nonprotonated amines as proton sponges.15 Both conditions
appeared fulfilled for S18[dN]19. To define the influence of the
amine/phosphate balance on cell entry of oligonucleotide-
oligospermine conjugates, we synthesized a series of fluorescent,
nuclease-resistant, phosphorothioate oligonucleotides with an in-
creasing number of 5′-appended spermine residues (Sn[dN]12, n )
0, 2, 5, 8, and 11, Supporting Information). As expected, only long-
term (24 h) incubation of HeLa cells with 5 µM [dN]12 led to visible
fluorescence accumulation (in lysosomes), presumably as a con-
sequence of pinocytosis. S2[dN]12 showed intracellular distribution
similar to [dN]12 in these conditions (not shown).
A quite different, starry intracellular distribution was seen with
S5[dN]12 even with shorter incubation times and lower concentra-
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Figure 1. Structure of 5′-spermine-conjugated oligonucleotides [N]m.
Figure 2. Intracellular distribution of fluorescent Sn[dN]m oligonucle-
otides. n, m, concentration (µM), incubation time (h); (a) 18, 19, 2, 4;
(b) 5, 12, 2, 4; (c) 11, 12, 2, 0.5; (d) 11, 12, 2, 0.5; (e) 8, 12, 2, 4. (a-c)
HeLa cells; (d, e) A549 cells.
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tions (Figure 2b). This distribution was reminiscent of endosome-
trapped complexes observed using cationic vectors.16 More inter-
esting, S11[dN]12 led to robust and diffuse labeling of the cells
(Figure 2c), reflecting endosome escape into the cytoplasm. This
effect was confirmed on another cell type (A549 cells, Figure 2d).
S8[dN]12 showed intermediate behavior, with intracellular patches
distributed within a fluorescent cytoplasm (Figure 2e).
Carrier-mediated delivery is dependent on the carrier-to-nucleic
acid charge ratio (N/P, since borne usually by amine and phosphate
groups). Full amine protonation of Sn[dN]12 is occurring as long as
the ampholyte’s total charge is not cationic.17 S5[dN]12 (N/P) 1.25,
see Figure 1) and upper homologues can therefore bind to
polyanionic HSPGs and be taken up into endosomes. When the
number of amines largely exceeds the number of phosphates,
individual amine pK’s gradually decrease and become capable of
acting as proton sponges. The diffuse cytoplasmic fluorescence
pattern observed with S8[dN]12 (N/P ) 1.6) indicates that
oligonucleotide-oligospermine conjugates with the formal charge
ratio N/P > 1.5 have indeed increased access to the cytoplasm.
siRNAs are 19-mer double-stranded RNA molecules with 3′-
dT2 overhangs that efficiently inhibit gene expression. Only the
antisense strand is required during the target mRNA cleavage step.
According to this and to the charge ratio required for cytoplasmic
release, we conjugated 30 spermines 5′ to the siRNA sense strand
(N/P ) 1.7; Supporting Information). Endogeneous gene silencing
was tested on A549Luc cells stably expressing large amounts of
luciferase ((1-2) × 1010 RLU/mg protein). As shown in Figure 3,
a concentration-dependent luciferase expression knockdown was
observed (S30, red bars), which was not observed with a shorter
S20 tail and did not improve with a longer S40 tail (green bars).
Negative control experiments using the “naked” S0 siRNA without
spermine, or an S30 siRNA containing 3 sequence mismatches (gray
bar), showed no luciferase silencing at 400 nM. Interestingly,
conjugation of S30 5′ to the antisense strand resulted in loss of
activity (Figure 3). This gives further credit to the silencing
mechanism induced by Sn siRNA, since the antisense strand
requires intracellular 5′-phosphorylation to become effective.
Charge-dependent toxicity was observed in the absence of serum,
as shown by a 33% (S30 siRNA) and 41% (S40 siRNA) decrease
of cellular proteins 48 h after incubation with 400 nM oligonucleotide.
In summary, cationic spermine-conjugated siRNAs enter human
cells and perform gene silencing in the submicromolar concentration
range. Although less effective in Vitro than recent cationic lipid
formulations which sediment onto the cells (Figure 3, “transfected”
gray bar using 10 or 100 nM siRNA), molecular siRNA drugs may
outclass nanoparticles in ViVo, where extracellular diffusion is a
major concern. Whether cationic siRNAs will withstand in ViVo
conditions, particularly RNase degradation, rests on chemistry and
further optimization. Work along these lines is in progress.
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Figure 3. Luciferase gene silencing in A549Luc cells using 5′-sense
oligospermine (Sn)-conjugated siRNA. Silencing is increasing with con-
centration (red bars) and number of spermine residues (green bars); gray
bars: negative and positive controls.
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